Lupin

Lupin dips 4%, hits seven-week low; what's making the Street nervous?

In the past month, Lupin underperformed the market by falling 9 per cent, as against a 1.4 per cent gain in the BSE Sensex and a 2.6 per cent rally in the BSE Healthcare index.

Lupin Q1FY27 result: Net profit rises 16% to ₹1,417 crore on strong growth

Homegrown pharma major Lupin Ltd has reported a 16 per cent rise in consolidated profit after tax at Rs 1,416.98 crore in the first quarter ended June 30, riding on robust growth across its key markets. The company had posted a consolidated Profit After Tax (PAT) at Rs 1,221.46 crore in the corresponding period last fiscal, Lupin Ltd said in a regulatory filing on Thursday. Consolidated total revenue from operations in the first quarter was at Rs 8,276.89 crore as against Rs 6,268.34 crore in the year-ago period, it added. Total expenses in the quarter under review rose at Rs 6,389.83 crore as compared to Rs 4,931.84 crore in the corresponding period last fiscal, the company said. Commenting on the performance, Lupin Ltd Managing Director Nilesh Gupta said, "We are pleased to begin FY27 with a strong performance, driven by robust growth across our key markets and continued improvement in profitability." The company's focus on execution, operational excellence, and sustained ...

Trump's 200% tariffs on imported generic medicines to test India's edge

Imported generics to remain tariff-free for two years; industry doubts US can build a cost-competitive manufacturing ecosystem within the transition period

Glenmark, Biocon, Aurobindo slip 3% on Trump's generic drug tariff plan

The US President Donald Trump announced a proposal to impose phased tariff (up to 200%) regime on imported generic medicines aimed at encouraging pharmaceutical manufacturing within the United States.

Lupin spins out 2 cancer drug programmes into US-based Kaveri Therapeutics

New company to raise capital for global clinical trials; Lupin to retain significant equity stake and provide seed funding

Pharma stocks: Lupin, Torrent hit new peaks; Sun nears summit; here's why

Pharma stock rally: Orchid Pharma, Hikal, Unichem Labs, IOL Chemicals, SPARC, RPG Life Sciences and Acutaas Chemicals surged up to 13% in Wednesday's trade.

Nifty Pharma rallies 2%; Laurus, Ipca, Aurobindo, Torrent hit record highs

In the past month, the Nifty Pharma index outperformed the market by surging 7.4 per cent, as compared to 4.2 per cent rise in the Nifty 50.

Stocks to Watch today: Bharti Airtel, Lupin, CSM Technologies, Coal India

Stocks to Watch today, July 2, 2026: Hero MotoCorp, Tata Technologies, Medi Assist Healthcare, and NLC India are among the top stocks to remain in focus during today's trading session.

Nifty Pharma index up 2%; Dr Reddy's, Ajanta, Ipca, Cipla surge up to 5%

In the past seven trading days, the Nifty Pharma index outperformed the market by soaring 5.4 per cent, as compared to 0.1 per cent decline in the Nifty 50.

Lupin gets tentative US FDA approval for generic prostate cancer drug

The tentative approval allows Lupin to market the generic prostate cancer treatment in the US after patent and exclusivity barriers expire

Patent expiry: A $5 bn opportunity for Indian pharma majors, says report

Lupin, Intas Pharmaceuticals, Sun Pharma, MSN Laboratories, Natco Pharma, Zydus Life Sciences and Dr Reddy's Laboratories are some of the companies, the note said, that could potentially benefit.

Stocks to Watch today: RIL, Lupin, Wipro, Asian Paints, Ireda, Tata Elxsi

Stocks to Watch today, May 29, 2026: Ashok Leyland, Alkem Laboratories, PhysicsWallah, GMR Airports, InterGlobe Aviation, NMDC, and Glenmark Pharma are among the top stocks to remain in focus today

Why pharma stocks are emerging as safe bet amid global market turmoil

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Stocks to watch today: Adani stocks, JSW Steel, Indian Oil, Astral, Lupin

Stocks to Watch today, May 19, 2026: Adani Group stocks, Indian Oil, JSW Steel, Astral, and Lupin are some of the key stocks to watch today

Nifty Pharma index soars 3%; Dr Reddy's, Piramal Pharma rally up to 9%

Glenmark Pharma, Cipla, Wockhardt, Mankind Pharma, Lupin, Zydus Life, Laurus, Ipca Labs, Divis Labs, Strides Pharma and Onesource were up in the range of 3% to 6%.

USFDA flags 3 manufacturing compliance lapses at Lupin's New Jersey unit

Pharma major Lupin Ltd on Saturday said the US health regulator has issued Form 483 with three observations to its Somerset, New Jersey, facility in the US following an inspection. The USFDA has concluded the inspection at our manufacturing facility located in Somerset, New Jersey, USA, Lupin said in a regulatory filing. "The inspection was conducted from April 13, 2026, to April 17, 2026, and closed with the issuance of a Form-483 with three observations," it added. The company further said, "We will address the observations and respond to the USFDA within the stipulated timeframe". Lupin said it is "committed to be compliant with CGMP standards across all our facilities". According to the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food, Drug and Cosmetic (FD&C) Act and related Acts.

Lupin's US arm signs $30 million litigation settlement with Humana Inc

Pharma major Lupin Ltd on Friday said its arm Lupin Pharmaceuticals, Inc USA has entered into a USD 30 million settlement agreement with Humana Inc for litigation over alleged anti-competitive practices. Lupin Pharmaceuticals, Inc USA (LPI) has been involved in multiple civil lawsuits alleging anti-competitive behaviour related to certain products and violation of federal and state antitrust laws. These multiple civil lawsuits were then combined into the collection of similar cases referred to as 'In Re Generic Pharmaceuticals Antitrust Litigation' located in Philadelphia, Pennsylvania, Lupin said in a regulatory filing. "While LPI denies the allegations, bu considering that other defendants have recently settled the case and in order to avoid the costs and uncertainties of continued litigation, LPI has entered into a settlement agreement with one of the plaintiffs namely Humana Inc. (Humana)," it added. Under the terms of the agreement, LPI will pay USD 30 million in consideration

Lupin arm settles US antitrust litigation with Humana for $30 million

Lupin says its US subsidiary will pay $30 million to Humana to settle antitrust claims, adding the amount has already been provided for and does not impact current financials

Pharma cos brace for soft Q4; US drag persists; domestic growth cushions

Pharma sector may see a 7 per cent Y-o-Y growth in reported sales and a 1 per cent increase in Ebitda, led by steady ex-gRevlimid US sales, healthy domestic growth, and favourable forex movements

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.